24/7 Market News Snapshot 06 May, 2025 – Heron Therapeutics, Inc. (NASDAQ:HRTX)

May 6, 2025

DENVER, Colo., 06 May, 2025 (www.247marketnews.com) – (NASDAQ:HRTX) are discussed in this article.
Heron Therapeutics, Inc. is experiencing significant positive momentum in the market, having opened at $2.44 and currently trading at $2.542, a substantial increase of 19.34% from the previous close of $2.130. This increase is underscored by a trading volume of 4.07 million shares, indicating heightened investor interest potentially linked to favorable developments or upcoming news. The stock is approaching key resistance levels, with continued trading above $2.54 suggesting further bullish trends. Support appears to be solid around the previous closing price of $2.130, prompting investors to closely monitor volume fluctuations and market responses for future direction.

Alongside this strong market performance, Heron has also announced impressive financial outcomes in its first quarter of 2025. The company reported net revenues of $38.9 million, reflecting a remarkable 12.2% increase year-over-year and driven largely by its acute care franchise, which recorded close to 89.4% revenue growth. Notably, ZYNRELEF, Heron’s flagship product, achieved robust revenue growth of 60.4%, affirming its solid market position.

In a strategic development, Heron secured a settlement with Mylan Pharmaceuticals concerning patent litigation for its products CINVANTI® and APONVIE®. Under this agreement, Mylan will be permitted to launch their generic versions in the U.S. starting June 1, 2032. CEO Craig Collard expressed a positive outlook, stating, “We are off to a strong start in 2025, achieving record adjusted EBITDA for the first quarter.”

With adjustments to its full-year EBITDA guidance now set between $4 million to $12 million, Heron Therapeutics is positioned to leverage its innovations and partnerships to enhance patient care and ensure sustained growth in the biotechnology sector.

Related news for (HRTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.